Compound Radar

Verastem, Inc. (VSTM) Stock Analysis

United States · Healthcare / Biotechnology

Price $9.59
Market cap $1.18B
Next earnings Nov 5, 2026
Entry status Watch

Last updated Nov 2, 2026

Health Check

Last analyzed Nov 2, 2026

40
40/100 Avoid
  • Financial Health 15
  • Profitability 15
  • Business Quality 65
  • Balance Sheet 65
  • Cash Flow 60

Why this rating?

Health 40/100 — Avoid

Strongest Business Quality 65/100
Softest Profitability 15/100
Watch

Worth tracking, but timing is mixed — not a clear setup yet.

Company overview

Verastem, Inc. (VSTM) is a Biotechnology company in the Healthcare sector. Compound Radar rates Verastem, Inc. 40/100 (Avoid) due to strong revenue growth and elevated leverage.

Investment profile

  • Quality Avoid
  • Growth Strong
  • Balance Sheet Stretched

Financial highlights

Valuation

  • Forward P/E -7.99
  • EV/Revenue 9.49

Profitability

  • Revenue Growth 1775.4%
  • Gross Margin 87.6%
  • Operating Margin -81.6%
  • Net Margin -231.6%
  • ROE -471.2%

Financial strength

  • Cash $136.35M
  • Debt $84.33M
  • Net Cash $52.02M
  • Free Cash Flow $-147.13M
  • Current Ratio 2.26

Similar companies

Peers in Biotechnology, ranked by Financial Health.

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Verastem, Inc. (VSTM).

View Methodology & FAQ →